Acute toxicity of hypofractionated radiotherapy for Japanese breast cancer patients after surgery: a single center prospective observational study (HyPORT-BC)-Reference-Cited by-同舟云学术

Acute toxicity of hypofractionated radiotherapy for Japanese breast cancer patients after surgery: a single center prospective observational study (HyPORT-BC)

Published:2024-08-08 Issue: Volume: Page:
ISSN:1340-6868
Container-title:Breast Cancer
language:en
Short-container-title:Breast Cancer

Author:

Nakamura Masaki^ORCID,Fujisawa Takeshi,Oyoshi Hidekazu,Zhou Yuzheng,Fukushi Keiko,Hirata Hidenari,Tomizawa Kento,Motegi Atsushi,Hojo Hidehiro,Wakabayashi Masashi,Kano Kazuto,Ohno Risa,Nakamura Azusa,Yamaguchi Masayuki,Zenda Sadamoto

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12282-024-01626-x.pdf

Reference17 articles.

1. Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, et al. Customizing local and systemic therapies for women with early breast cancer: The St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32:1216–35. https://doi.org/10.1016/j.annonc.2021.06.023.

2. Meattini I, Becherini C, Boersma L, Kaidar-Person O, Marta GN, Montero A, et al. European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncol. 2022;23:e21-31. https://doi.org/10.1016/S1470-2045(21)00539-8.

3. Brunt AM, Haviland JS, Sydenham M, Agrawal RK, Algurafi H, Alhasso A, et al. Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer. J Clin Oncol. 2020;38:3261–72. https://doi.org/10.1200/JCO.19.02750.

4. Murray Brunt A, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395:1613–26. https://doi.org/10.1016/S0140-6736(20)30932-6.

5. Lewis P, Brunt AM, Coles C, Griffin S, Locke I, Roques T, et al. Moving forward fast with FAST-Forward. Clin Oncol (R Coll Radiol). 2021;33:427–9. https://doi.org/10.1016/j.clon.2021.04.007.